|
1
|
Jemal A, Bray F, Center MM, et al: Global
cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Shiraha H, Yamamoto K and Namba M: Human
hepatocyte carcinogenesis (review). Int J Oncol. 42:1133–1138.
2013.PubMed/NCBI
|
|
3
|
Llovet JM, Burroughs A and Bruix J:
Hepatocellular carcinoma. Lancet. 362:1907–1917. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Mínguez B and Lachenmayer A: Diagnostic
and prognostic molecular markers in hepatocellular carcinoma. Dis
Markers. 31:181–190. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Cheng AL, Kang YK, Chen Z, et al: Efficacy
and safety of sorafenib in patients in the Asia-Pacific region with
advanced hepatocellular carcinoma: a phase III randomised,
double-blind, placebo-controlled trial. Lancet Oncol. 10:25–34.
2009. View Article : Google Scholar
|
|
6
|
Llovet JM, Ricci S, Mazzaferro V, et al:
SHARP Investigators Study Group: Sorafenib in advanced
hepatocellular carcinoma. N Engl J Med. 359:378–390. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
El-Serag HB: Hepatocellular carcinoma:
recent trends in the United States. Gastroenterology. 127(5 Suppl
1): S27–S34. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Herath NI, Leggett BA and MacDonald GA:
Review of genetic and epigenetic alterations in
hepatocarcinogenesis. J Gastroenterol Hepatol. 21:15–21. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kanda M, Nomoto S, Nishikawa Y, et al:
Correlations of the expression of vascular endothelial growth
factor B and its isoforms in hepatocellular carcinoma with
clinico-pathological parameters. J Surg Oncol. 98:190–196. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Miki D, Ochi H, Hayes CN, Aikata H and
Chayama K: Hepatocellular carcinoma: towards personalized medicine.
Cancer Sci. 103:846–850. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Villanueva A, Newell P, Chiang DY,
Friedman SL and Llovet JM: Genomics and signaling pathways in
hepatocellular carcinoma. Semin Liver Dis. 27:55–76. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kanda M, Nomoto S, Okamura Y, et al:
Detection of metallothionein 1G as a methylated tumor suppressor
gene in human hepatocellular carcinoma using a novel method of
double combination array analysis. Int J Oncol. 35:477–483.
2009.PubMed/NCBI
|
|
13
|
Sang M, Wang L, Ding C, et al:
Melanoma-associated antigen genes-an update. Cancer Lett.
302:85–90. 2011. View Article : Google Scholar
|
|
14
|
Chang CC, Campoli M, Luo W, et al:
Immunotherapy of melanoma targeting human high molecular weight
melanoma-associated antigen: potential role of nonimmunological
mechanisms. Ann NY Acad Sci. 1028:340–350. 2004. View Article : Google Scholar
|
|
15
|
Barker PA and Salehi A: The MAGE proteins:
emerging roles in cell cycle progression, apoptosis, and
neurogenetic disease. J Neurosci Res. 67:705–712. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Xiao J and Chen HS: Biological functions
of melanoma-associated antigens. World J Gastroenterol.
10:1849–1853. 2004.PubMed/NCBI
|
|
17
|
Langnaese K, Kloos DU, Wehnert M, Seidel B
and Wieacker P: Expression pattern and further characterization of
human MAGED2 and identification of rodent orthologues. Cytogenet
Cell Genet. 94:233–240. 2001. View Article : Google Scholar
|
|
18
|
Oya H, Kanda M, Takami H, et al:
Overexpression of melanoma-associated antigen D4 is an independent
prognostic factor in squamous cell carcinoma of the esophagus. Dis
Esophagus. Oct 21–2013.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Takami H, Kanda M, Oya H, et al:
Evaluation of MAGE-D4 expression in hepatocellular carcinoma in
Japanese patients. J Surg Oncol. 108:557–562. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sobin LH, Gospodarowicz MK and Wittekind
C: International Union Against Cancer. TNM classification of
malignant tumors. 7th edition. Wiley-Blackwell; New York, NY:
2009
|
|
21
|
Kanda M, Nomoto S, Okamura Y, et al:
Promoter hypermethylation of fibulin 1 gene is associated with
tumor progression in hepatocellular carcinoma. Mol Carcinog.
50:571–579. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
22
|
Arzumanyan A, Reis HM and Feitelson MA:
Pathogenic mechanisms in HBV- and HCV-associated hepatocellular
carcinoma. Nat Rev Cancer. 13:123–135. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Khare S, Zhang Q and Ibdah JA: Epigenetics
of hepatocellular carcinoma: role of microRNA. World J
Gastroenterol. 19:5439–5445. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hernandez-Gea V, Toffanin S, Friedman SL
and Llovet JM: Role of the microenvironment in the pathogenesis and
treatment of hepatocellular carcinoma. Gastroenterology.
144:512–527. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kanda M, Nomoto S, Oya H, et al:
Downregulation of DENND2D by promoter hypermethylation is
associated with early recurrence of hepatocellular carcinoma. Int J
Oncol. 44:44–52. 2014.
|
|
26
|
Bertrand M, Huijbers I, Chomez P and De
Backer O: Comparative expression analysis of the MAGED genes during
embryogenesis and brain development. Dev Dyn. 230:325–334. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Harper R, Xu C, Di P, et al:
Identification of a novel MAGE D2 antisense RNA transcript in human
tissues. Biochem Biophys Res Commun. 324:199–204. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kidd M, Modlin IM, Mane SM, et al: The
role of genetic markers - NAP1L1, MAGE-D2, and MTA1 - in defining
small-intestinal carcinoid neoplasia. Ann Surg Oncol. 13:253–262.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Papageorgio C, Brachmann R, Zeng J, et al:
MAGED2: a novel p53-dissociator. Int J Oncol. 31:1205–1211.
2007.PubMed/NCBI
|
|
30
|
Kidd M, Modlin IM, Mane SM, et al: Utility
of molecular genetic signatures in the delineation of gastric
neoplasia. Cancer. 106:1480–1488. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Li M, Lin YM, Hasegawa S, et al: Genes
associated with liver metastasis of colon cancer, identified by
genome-wide cDNA microarray. Int J Oncol. 24:305–312.
2004.PubMed/NCBI
|
|
32
|
Tseng HY, Chen LH, Ye Y, et al: The
melanoma-associated antigen MAGE-D2 suppresses TRAIL receptor 2 and
protects against TRAIL-induced apoptosis in human melanoma cells.
Carcinogenesis. 33:1871–1881. 2012. View Article : Google Scholar : PubMed/NCBI
|
